Systemic treatment of metastatic melanoma with chemotherapy

Hematology/Oncology Clinics of North America

Volumn 12, Issue 4, 1998, Pages 863-875

  Green, R J ^a   Schuchter, L M ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; DACARBAZINE; DOCETAXEL; ESTROGEN RECEPTOR; FOTEMUSTINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; INTERFERON; INTERLEUKIN 2; LOMUSTINE; MELACINE; MELANOMA VACCINE; NITROSOUREA DERIVATIVE; PACLITAXEL; PHOSPHORYL LIPID A; SEROTONIN 3 ANTAGONIST; TAMOXIFEN; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE; VINDESINE;

BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG TOXICITY; MELANOMA; METASTASIS; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031706605     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70028-9     Document Type: Article

References (51)

1. D.L. Ahmann E.T. Creagan R.G. Hahn Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma Cancer 63 1989 224 227
2. S.S. Argawala J.M. Kirkwood Interferons in melanoma Curr Opin Oncol 8 1996 167 174
3. M.B. Atkins The treatment of metastatic melanoma with chemotherapy and biologics Curr Opin Oncol 9 1997 205 213
4. M.B. Atkins K.R. O'Boyle J.A. Sosman Multi-institutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma J Clin Oncol 12 1994 1553 1560
5. Balch C.M. Soong J.-J. T.M. Murad A multifactorial analysis of melanoma: IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III) J Clin Oncol 1 1983 126
6. A. Barth L.A. Wanek D.L. Morton Prognostic factors in 1521 melanoma patients with distant metastases J Am Coll Surg 181 1995 193 201
7. A.Y. Bedikian G.R. Weiss S.S. Legha Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy J Clin Oncol 13 1995 2895 2899
8. N.M. Bleehen S.M. Newlands L.N. Thatcher Cancer research campaign phase II trial of temozolomide in metastatic melanoma J Clin Oncol 13 1995 910 913
9. A.C. Buzaid S.S. Legha Combination of chemotherapy with interleukin-2 and interferon-alfa for the treatment of advanced melanoma Semin Oncol 21 1994 23 28
10. G. Cocconi M. Bella F. Calabresi Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen N Engl J Med 327 1992 516 523
11. Del Prete S.A. L.H. Maurer J. O'Donnell Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma Cancer Treat Rep 68 1984 1403 1405
12. P.A. Demchak J.W. Mier N.J. Robert Interleukin-2 and high-dose cisplatin in patients with metastic melanoma: A pilot study J Clin Oncol 9 1991 1821 1830
13. K. Dhingra N. Papadopoulos S. Lippman Phase II study of alpha-interferon and 13-cis-retinoic acid in metastatic melanoma Invest New Drugs 11 1993 39 43
14. T. Dorval S. Negrier C. Chevreau Results of a French multicentric randomized trial of chemoimmunotherapy with or without interferon in metastatic malignant melanoma Proc Am Soc Clin Oncol 13 1994 A1347
15. A. Einzig L.M. Schuchter Phase II trial of docetaxel (taxotere) in patients with metastatic melanoma Med Oncol 13 1996 111 117
16. C.I. Falkson J. Ibrahim J. Kirkwood A randomized phase III trial of dacarbazine (DTIC) versus DTIC + interferon alfa-2b (IFN) versus DTIC + tamoxifen (TMX) versus DTIC + IFN + TMX in metastatic malignant melanoma: An ECOG Trial Proc Am Soc Clin Oncol 15 1996 A1350
17. R.I. Fisher J.P. Neifeld M.E. Lippman Oestrogen receptors in human malignant melanoma Lancet 2 1976 337 339
18. L.E. Flaherty P.Y. Liu W.S. Fletcher Dacarbazine and outpatient interleukin-2 in treatment of metastatic malignant melanoma: A phase II Southwest Oncology Group trial J Natl Cancer Inst 84 1992 893 894
19. L.E. Flaherty P.Y. Liu J. Unger Comparison of patient characteristics and outcome between a single-institution phase II trial and a cooperative-group phase II trial with identical eligibility in metastatic melanoma Am J Clin Oncol 20 1997 600 604
20. L.E. Flaherty W. Robinson B.G. Redman A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma Cancer 71 1993 3520 3525
21. Guerry D. IV L.M. Schuchter Disseminated melanoma—is there a new standard therapy? N Engl J Med 327 1992 560 561
22. Hill G. II E. Krementz H. Hill Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy. Central Oncology Group Protocols 7130, 7131, and 7131A Cancer 53 1984 1299
23. J. Hofmann W. Doppler A. Jakob Enhancement of the antiproliferative effect of cis-diamminedichloroplatinum (II) and nitrogen mustard by inhibitors of protein kinase C Int J Cancer 42 1988 382 388
24. C. Jacquillat D. Khayat P. Banzet Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases Cancer 66 1990 1873 1878
25. U. Keilholz S.H. Goey C.J. Punt Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: A randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group J Clin Oncol 15 1997 2579 2588
26. D. Khayat M. Avril G. Auclerc Clinical value of the nitrosourea fotemustine in disseminated malignant melanoma: Overview on 1022 patients including 144 patients with cerebral metastases Proc Am Soc Clin Oncol 12 1993 A1343
27. D. Khayat C. Borel J.M. Tourani Sequential chemoimmunotherapy with cisplatin, interleukin-2 and interferon alfa-2a for metastatic melanoma J Clin Oncol 11 1993 2173 2180
28. S.M. Lee D.C. Betticher N. Thatcher Melanoma: Chemotherapy Br Med Bull 51 1995 609 630
29. S.S. Legha Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy Semin Oncol 24 1997 S39 S43
30. S.S. Legha A.C. Buzaid Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatment of advanced melanoma Semin Oncol 20 suppl 9 1993 27 32
31. S. Legha A. Buzaid A. Bedikian Efficacy of concurrent biochemotherapy using interleukin-2 (IL-2) + interferon alfa-2a (IFN) and chemotherapy with cisplatin (C), vinblastine (V) and DTIC (D) in metastatic melanoma [abstract] Proc Annu Meet Am Assoc Cancer Res 35 1994 A520
32. S. Legha A.C. Buzaid S. Ring Improved results of treatment of metastatic melanoma with combined use of biotherapy and chemotherapy (biochemo) [abstract] Proc Annu Meet Am Soc Clin Oncol 13 1994 A1343
33. S.S. Legha S. Ring A. Bedikian Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha Ann Oncol 7 1996 827 835
34. S.S. Legha S. Ring N. Papadopoulos A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma Cancer 64 1989 2024 2029
35. Margolin K. Liu P.-Y. L. Flaherty Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: A Southwest Oncology Group study J Clin Oncol 16 1997 664 669
36. E.F. McClay M.E.T. McClay Tamoxifen: Is it useful in the treatment of patients with metastatic melanoma? J Clin Oncol 12 1994 617 626
37. E.F. McClay M.J. Mastrangelo R.E. Bellet Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma Cancer Treat Rep 71 1987 465 469
38. E.F. McClay M.J. Mastrangelo D. Berd Effective combination chemo/hormonal therapy for malignant melanoma: Experience with three consecutive trials Int J Cancer 50 1992 553 556
39. E.F. McClay M.J. Mastrangelo J.D. Sprandio The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma Cancer 63 1988 1292 1295
40. E.F. McClay K.D. Albright J.A. Jones Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells Cancer Res 53 1993 1571 1576
41. D.F. McDermott J.W. Mier D.P. Lawrence A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine (CVD), interleukin-2 (IL-2) and interferon alpha-2b (IFN) in patients with metastatic melanoma Proc Am Soc Clin Oncol 490a 1997
42. Mitchell M.S. Bon Eschen K.B. Phase III trial of Melacine melanoma theraccine versus combination chemotherapy in the treatment of stage IV melanoma Proc Am Soc Clin Oncol 1997 A1778
43. R.A. Nesbit R.L. Woods M.H. Tattersall Tamoxifen in malignant melanoma [letter] N Engl J Med 301 1979 1241 1242
44. I. Parish Am J Med Sci 20 1837 266 268
45. J.M. Richards N. Mehta K. Ramming Sequential chemotherapy/immunotherapy in the treatment of metastatic melanoma J Clin Oncol 10 1992 1388
46. J. Richards N. Mehta L. Schroeder Sequential chemotherapy/immunotherapy for metastatic melanoma [abstract] Proc Annu Meet Am Soc Clin Oncol 11 1992 A1189
47. R.E. Royal S.M. Steinberg D. White Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma Cancer Journal From Scientific American 6 1996 91 98
48. P. Rumke U.R. Kleeberg R.M. MacKie Tamoxifen as a single agent for advanced melanoma in postmenopausal women. A phase II study of the EORTC Malignant Melanoma Cooperative Group Melanoma Res 2 1992 153 156
49. J.J. Rusthoven I.C. Quirt N.A. Iscoe Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma J Clin Oncol 14 1996 2083 2090
50. G. Stoter S. Aamdal S. Rodenhuis Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: A multicenter phase II study J Clin Oncol 9 1991 1687 1691
51. J.A. Thompson P.J. Gold A. Fefer Outpatient chemoimmunotherapy for the treatment of metastatic melanoma Semin Oncol 24 1997 S4